Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
about
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionNew advances in targeted gastric cancer treatmentUsing Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular CarcinomaMolecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesVascular gene expression patterns are conserved in primary and metastatic brain tumors.Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor GrowthZerumbone, Sesquiterpene Photochemical from Ginger, Inhibits Angiogenesis.Antiangiogenic platinum through glycan targeting.FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteersTarget validation to biomarker development: focus on RNA interference.An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screeningPersonalized therapies in the cancer "omics" eraPreclinical development of molecular-targeted agents for cancer.Brivanib alaninate for cancer.Brivanib: a review of development.A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.A FGFR1 inhibitor patent review: progress since 2010.Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer.Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
P2860
Q24616631-20B52DC4-4057-4BBB-969F-B86509D3FCEDQ26738548-1DC3E671-83DC-4153-B7CE-EA6E54997008Q26797535-9EE1B2F2-A0F3-44C3-A86C-B6F2836B425CQ28079232-70C35C72-C68A-4136-82AF-11BA767C337BQ33996790-C38C110B-8323-4EA2-9FE5-938EFB0BAADBQ35141906-BC74147E-6E10-4765-AED7-4186F290E6B0Q35251663-B7125041-28A9-48F3-A6E6-B44F1480285FQ35843962-8FD29371-8A4B-4796-8751-1FAA0593A4AEQ36357296-28E31811-299F-490C-A756-2C8428FAD5E1Q36524946-8088715B-CCA9-4C85-8E33-23A8288481F8Q36755179-5096760F-648B-4AF4-8970-771471CAD407Q37141990-B050B2A3-54E3-4C4E-B6B7-F802EE02D373Q37206514-7441724D-5DB4-40FF-834A-3BA7C4F37E45Q37231567-F1494E0A-3127-43C7-9A76-34808A358FEDQ37776547-A996D4C8-E0A9-4FB0-ADFC-525FD24E1F22Q37816960-FCBF4A7F-4E56-4306-8FED-BBFD433516E3Q37851518-ACEA59B2-F231-4C63-B7E7-97138AE713AFQ38048883-96FD0F32-7166-4F59-81DE-E665F0A81D54Q38669565-F9A20A6A-6203-45CA-A97C-955AAE087E4AQ38782612-F7905EA3-E481-42A8-BC9A-84529CA38EB4Q39062384-BC8AC509-3A2D-427C-815A-7B07E6360A56Q39091444-E0098968-D9BD-4172-AA5A-0E267220C3C8Q42198612-8059858C-1257-40AC-BDCD-240900D75DC5Q51048190-62912641-D28A-4DF4-BDE0-B73BE1D24F48
P2860
Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@ast
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@en
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@nl
type
label
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@ast
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@en
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@nl
prefLabel
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@ast
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@en
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@nl
P2093
P1433
P1476
Discovery and validation of bi ...... ule VEGFR-2/FGFR-1 antagonist.
@en
P2093
Anne Lewin
J Suso Platero
Joseph Fargnoli
Mark Ayers
P304
P356
10.1158/0008-5472.CAN-06-4555
P407
P577
2007-07-01T00:00:00Z